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OBJECTIVES: Conventional imaging methods are excellent for the morphological characterization of the
consequences of osteonecrosis; however, only specialized techniques have been considered useful for obtaining
functional information. To explore the affinity of radiotracers for severely devascularized bone, a new mouse
model of isolated femur implanted in a subcutaneous abdominal pocket was devised. To maintain animal
mobility and longevity, the femur was harvested from syngeneic donors. Two technetium-99m-labeled tracers
targeting angiogenesis and bone matrix were selected.
METHODS: Medronic acid and a homodimer peptide conjugated with RGDfK were radiolabeled with
technetium-99m, and biodistribution was evaluated in Swiss mice. The grafted and control femurs were
evaluated after 15, 30 and 60 days, including computed tomography (CT) and histological analysis.
RESULTS: Radiolabeling achieved high (495%) radiochemical purity. The biodistribution confirmed good blood
clearance 1 hour after administration. For 99mTc-hydrazinonicotinic acid (HYNIC)-E-[c(RGDfK)2, remarkable renal
excretion was observed compared to 99mTc-methylene diphosphonate (MDP), but the latter, as expected,
revealed higher bone uptake. The results obtained in the control femur were equal at all time points. In the
implanted femur, 99mTc-HYNIC-E-[c(RGDfK)2 uptake was highest after 15 days, consistent with early angio-
genesis. Regarding 99mTc-MDP in the implant, similar uptake was documented at all time points, consistent with
sustained bone viability; however, the uptake was lower than that detected in the control femur, as confirmed
by histology.
CONCLUSIONS: 1) Graft viability was successfully diagnosed using radiotracers in severely ischemic bone at all
time points. 2) Analogously, indirect information about angiogenesis could be gathered using 999mTc-HYNIC-E-
[c(RGDfK)2. 3) These techniques appear promising and warrant further studies to determine their potential
clinical applications.
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’ INTRODUCTION
Avascular bone ischemia and necrosis encompass a cluster
of orthopedic phenomena, which can affect multiple bones in
different settings. From unrecognized microfractures and
necrotic foci to total bone collapse and loss of function, these
conditions can lead to a variety of clinical courses. The idio-
pathic modality is the most studied, especially in subarticular
(subchondral) regions of the long bones, such as classic
Calve-Legg-Perthes disease of the head of the femur. Bone
infarcts can also occur secondary to embolisms of defective
red blood cell agglomerates, typical of sickle cell condi-
tions, and those associated with blood clots, fats and gas
embolisms (1,2).
Virtually any type of bone can be affected by such pre-
cipitants, which also include trauma (fractures and disloca-
tions), infections, alcoholism, rheumatologic disorders (e.g.,
lupus), radiotherapy (osteoradionecrosis), and the use of
certain drugs, particularly corticosteroids (1,2).
Moreover, these conditions are concerning when bone
grafts are therapeutically used to resolve clinical situations
with loss of bone substance. The viability of the transferred
graft plays a critical role in the mechanical and physiological
properties of the bone fragment.DOI: 10.6061/clinics/2016(10)11
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For example, temporary ischemia of large bone segments
with subsequent reimplantation can occur after decompres-
sive craniectomy to treat brain swelling. Depending on the
severity of the intracranial hypertension, primary closure of
the skull might become impossible, in which case, the flaps
must be stored until cranioplasty becomes feasible. Place-
ment in a subcutaneous pocket of the lower abdominal wall
for weeks or up to a month or more represents an alternative
method of preserving the bone flaps (3).
Large, unresectable chondrosarcomas and other tumors of
the calvaria, mandible and femur can rarely be extracorporeally
treated by autoclavation or other cancer sterilization proce-
dures, followed by reimplantation. Although the removed bone
does not require prolonged storage and can be orthotopically
replaced fairly promptly, the graft becomes totally devitalized,
and subsequent histological reactions can occur (4).
Experimental animal models of osteonecrosis are not
lacking, and an array of ischemic, traumatic and pharmaco-
logic induction options have become available (5,6,7). Most
have been aimed at Calve Legg Perthes disease and, thus,
require very detailed and cumbersome techniques (8).
Disability is intrinsic to such models, as seen in the human
context; however, these approaches can shorten survival and
hamper the long-term observation of the animals.
In the present protocol, a reliable, inexpensive, and easily
reproducible option was sought. Such a model should
reflect the general bone shifts that occur over the course of
prolonged total ischemia, not only those germane to aseptic
necrosis of the head of the femur. Freely moving animals
should also be included in the design to minimize the long-
term mortality triggered by partial or total immobilization.
Ideally, the model should provide a stable substrate for the
functional assessment of prolonged major bone ischemia.
Standard imaging methods, including computed tomo-
graphy (CT) and magnetic resonance imaging (MRI), are
excellent for diagnosing the established clinical consequences
of bone damage. However, their roles in functional follow-
up—namely, to determine the progression or regression of
bone viability—have not been demonstrated (1,7,8).
Biphosphonates radiolabeled with the radioisotope tech-
netium-99m (99mTc) (9,10) have been used as general bone
diagnostic imaging agents for decades. Therefore, they were
a logical choice for the assessment of bone function within
the context of this ischemia model. Angiogenesis, a func-
tional process involved in bone regeneration, includes many
mediators, such as integrins, and the tripeptide RGD
sequence is a target amino acid recognition sequence for
many of these mediators (11).
Evidence of angiogenesis was also within the scope of
this investigation because this phenomenon is directly
pertinent to bone viability, although molecular confirmation
of the involved radionuclide mediators and receptors was
outside the scope of this protocol.
Under these circumstances, a new model employing whole
femur grafts syngeneically implanted in subcutaneous
pouches in mice was devised and monitored for 60 days
by two different radiotracers: 99mTc-MDP and 99mTc-HYNIC-
E-[c(RGDfK)2.
The objective of this study was the longitudinal analysis of
large bone avascular necrosis in mobile animals. It was
hypothesized that a stable, reproducible and convenient
experiment would be achieved and that bone viability would
be successfully detected by systemically injected isotopes,
despite the constraint imposed by a lack of vascularization.
To the best of our knowledge, this model of osteonecrosis has
not been reported before, and this study represents the first
assessment of the radiotracer imaging technique (12).
’ MATERIALS AND METHODS
Compliance with ethical standards
The study was approved by the Institutional Animal
Welfare Committee of the Instituto de Pesquisas Energéticas
e Nucleares (IPEN)/Comissão Nacional de Energia Nuclear
(CNEN), São Paulo, SP, Brazil, and both the ‘‘Principles of
laboratory animal care" (NIH publication 8023, revised 1978
and 86-23, revised 1985) and the national guidelines for
animal experimentation, as established by the Scientific
Ethics Committee, Institute of Energy and Nuclear Research,
National Nuclear Energy Committee, Brazil, and the
Brazilian College of Animal Investigation, were followed.
Materials
a) The cyclic homodimer peptide-conjugated arginine-glycine-
aspartic acid and D-phenylalanine-lysine analog, with gluta-
mic acid connecting the dimers [abbreviated (HYNIC-E-[c
(RGDfK)2)] (MW 1453.6, peptide purity: 95%), was purchased
from CPC Scientific Inc. (Sunnyvale, CA, USA) as lyophilized
powder (Figure 1A). The conjugate was dissolved in sterile
water at a concentration of 687.94 mMandwas stored at -20oC.
b) A lyophilized medronic acid kit consisting of 10 mg of
medronic acid (Figure 1B), 1.2 mg of dehydrated stannous
chloride, and 2 mg of paraminobenzoic acid (produced
in house) was used (Radiopharmacy Center, Institute of
Energy and Nuclear Research/National Commission of
Nuclear Energy-IPEN/CNEN, São Paulo, SP, Brazil).
c) Technetium-99m (99mTc), in the form of Na99mTcO4, was
eluted in saline from an alumina-based 99Mo/99mTc
generator, which was supplied by the same radiophar-
macy center (IPEN/CNEN, São Paulo, SP, Brazil).
d) Silica gel strips (SGs) for instant thin-layer chromatogra-
phy (ITLC) (5  20 cm; Pall Corporation, NY, USA) and
chromatography paper (Whatman 3 MM; Fisher Scien-
tific, Loughborough, UK) were also used.
Figure 1 - Structure of conjugated HYNIC-E[c(RGDfK)]2 (A) and
methylene diphosphonic acid (MDP) (B).
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e) Reversed-phase high-performance liquid chromato-
graphy (RP-HPLC, Shimadzu, Kyoto, Japan) was performed
using a Symmetry C-18 column (5.0 mm, 100 Ao, 4.66250
mm, Waters, Milford, MA, USA). Radioactivity measure-
ments were collected using an automated, well-type
c-counter NaI(Tl) crystal (Canberra, Meriden, CT, USA).
Radiotracer preparation
Radiolabeling of MDP with technetium-99m. The
freeze-dried kit was reconstituted using 3 mL of freshly
eluted Na99mTcO4 in a sterile physiological saline solution
with an activity of 30 mCi (1,110 MBq). The vial was stirred
and maintained at room temperature for 15 min to allow the
reaction to proceed.
HYNIC-E-c(RGD)2 labeling with
99mTc using
ethylenediamine-N,N’-diacetic acid (EDDA)/tricine
as exchange products
The labeling procedure was performed as previously
described by our group (13).To a sealed reaction vial
containing 20 mg of tricine and 5 mg of EDDA, 0.5 mL of
previously nitrogenated 0.1 M phosphate-buffered saline
was added to dissolve the salts. Then, 10 ml of 687.94 mM
HYNIC-E-c(RGDfK)2 plus stannous chloride (SnCl2
.H2O)
in 0.1 N HCl (nitrogen-purged) and 500 mL of Na99mTcO4
-
(1850 MBq) were added. The vial was heated for 20 minutes
at 100oC and then cooled to room temperature. The pH of the
reaction was 7.
Radiochemical control
The radiochemical evaluation of 99mTc-MDP was per-
formed by ascending paper chromatography using Whatman
3 MM chromatography paper as the support; the two solvent
systems consisted of acetone and 0.9% sodium chloride
solution.
In contrast, ITLC-SG was used for the radiochemical
evaluation of 99mTc-HYNIC-E-[c(RGDfK)2 with a two solvent
system consisting of methylethylketone and 50% acetonitrile.
The ITLC results were confirmed by RP-HPLC using a
C18 column (5.0 mm, 100Ao, 4.6 x 250 mm) and a flow rate of
1.0 mL/min. The solvent system consisted of H2O containing
0.1% trifluoroacetic acid (solvent A) and acetonitrile contain-
ing 0.1% trifluoroacetic acid (solvent B). The HPLC gradient
system began with a solvent composition of 95% A and
5% B, followed by a linear gradient to 30% A:70% B from 0 to
25 min and, then, 5% A:95% B from 25 to 30 min.
Study end points
The primary end point was the successful uptake of
the two radiomarkers by totally devascularized bone grafts,
compatible with the vitality of the subcutaneously housed
ischemic bone. The secondary end point was the analysis of
the technical difficulties of the model and the radionuclide
procedure to gain insight into their future utility.
Biological studies and study samples
All in vivo studies were performed in young female inbred
Swiss mice (8 weeks old) with weights of approximately
20 g. Females were selected because they were more easily
available. Age and weight were defined for ease of handling
while excluding any age-related osteoporosis. Because this
study was the first of its kind and no previous reports are
available in the literature, formal sample size estimation
could not be performed. However, given the syngeneic
features and the homogeneous weight, age and sex of the
model, 6 mice for each isotope and observation time were
considered adequate to obtain statistically relevant findings.
The studied population was 54 mice divided into three
groups (one for each isotope and one for general purposes,
such as tomographic imaging, macroscopic evaluation, and
histological control), with 6 animals analyzed at each of the
three time points. Another 27 animals were used as femur
donors (two femurs from each donor), for a total of 81 mice.
All animals were sacrificed at the end of the corresponding
observation period and analyzed according to the protocol.
The exceptions were, naturally, the donors, which were all
sacrificed at the beginning of the investigation. The animals
were provided by the Animal Facility of IPEN/CNEN,
São Paulo, SP, Brazil.
Housing and handling of the animals
The mice were maintained in individual cages under a
12-h/12-h light/dark cycle and pathogen-controlled condi-
tions. They had ad libitum access to water and standard
rodent chow. All of the procedures were performed in the
morning in the technical laboratory. Radioactive materials,
including the sacrificed animals, were quarantined until
isotope decay and then discarded in accordance with inter-
national directives (International Atomic Energy Agency).
Biodistribution evaluation
The animals were sacrificed by anesthetic drug overdose
1 h after the administration of the radiotracer. Tissues and
organs were excised and weighed, and the radioactivity was
measured with a gamma counter (Cobra 5002, Packard,
USA), using the injected dose as a standard for calculation.
The results were expressed as the percentage of the injected
dose per gram (%ID/g).
Subcutaneous femur implantation
Donor animals were sacrificed by anesthetic overdose,
and their femurs were surgically excised. The homolateral
femurs were subcutaneously grafted into a surgically created
abdominal pouch. The animals were anesthetized (1 mL/kg
IP ketamine and 0.5 ml/kg IP xylazine) and shaved for the
surgical intervention.
A transverse skin incision was made on the right side of the
abdomen between the last rib and the hip. A pocket was
created for the implantation of the femoral graft. After the
femur was successfully placed, the incision was sutured. No
skin mark was necessary because the bone was easily palpable.
The mice were allowed to recover with food and water.
The water supplied during the first 5 days contained an
antibiotic (oxacillin) and an analgesic (acetaminophen).
Tomographic imaging
Whole-body tomographic images were acquired in a
Preclinical System PET/SPECT/CT (Bruker, Billerica, MA,
USA). For technical reasons, the follow-up times were
reduced to only two: baseline (bone implantation) and the
end of the experiment (60 days).
Radiotracer uptake in grafted vs. control femurs
After 15, 30 and 60 days, radiotracers were injected. For
the acquisition of images, the mice were anesthetized and
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horizontally placed under the low-energy, high-resolution
(LEHR) collimator of a Mediso Imaging System (Budapest,
Hungary). Images were acquired 3 min before sacrifice using
a 256 x 256 x 16 matrix size with a 20% energy window set at
140 keV for a period of 180 seconds.
The animals were then sacrificed. Both the grafted and
orthotopic homolateral control femurs were excised and
weighed, and the radioactivity was measured using a
gamma counter as described in item 4.
Grafted and control femurs were also created and har-
vested without the administration of radiotracers during the
same periods for histological analysis.
Macroscopic images of the specimens
Representative bone grafts were photographed at different
times for illustrative purposes. Because a hand-held appara-
tus and not photometric equipment or software was used,
minor imaging distortions may have occurred.
Histological evaluation
The excised femurs were fixed in buffered formalin
solution. Following decalcification for 30 days, they were
embedded in paraffin blocks. Representative slides from
mid-diaphysis and the subchondral areas (for comparison)
were then processed for routine hematoxylin and eosin
staining.
Statistical analysis
The radiolabeling results, tomographic images and histo-
logical sections were interpreted by professionals blinded to
the group and the timing of the experiments.
The results are presented as percentages or the means ±
standard deviations. Numerical findings were compared
using Student’s ‘‘t’’ test or analysis of variance using the
Statistical Package SPSS 17.0 (2012). Differences were
considered significant when po0.05.
’ RESULTS
The radiolabeling of both molecules with 99mTc resulted
in high radiochemical purity. The labeling efficiency for
99mTc-MDP was assessed by paper chromatography using a
solvent system and was found to be 97.42±0.89%. In both
solvents (acetone and 0.9% sodium chloride solution), the
impurity pertechnetate (99mTcO4) had a retention factor (Rf)
of 1, whereas the colloid 99mTcO2 impurity was quantified as
Rf=0. The radiolabeled 99mTc-MDP in the former solvent
remained with the colloid. In the latter solvent, the Rf was
the same as that for pertechnetate.
The radiochromatogram acquired via HPLC for
99mTc-HYNIC-E-c(RGDfK)2 demonstrated a single peak at
14.83 min, with a radiochemical purity of 98.85±0.23%.
The amount of the colloid (99mTcO2) was only detectable
by ITLC-SG and was found to be approximately 0.13%.
The biodistribution of radiotracers revealed good blood
clearance. Because the 99mTc-HYNIC-E-[c(RGDfK)2 conjugate
was relatively hydrophilic, remarkable renal excretion was
observed compared to 99mTc-MDP. Hepato-intestinal excre-
tion also occurred, whereas with 99mTc-MDP, only hepatic
excretion was noted, and the enteric concentrations were
very low. The uptake by the spleen was similar. 99mTc-MDP
exhibited much higher affinity for bone than 99mTc-HYNIC-E-
c(RGDfK)2, as expected.
Shortly after femur grafting (baseline), tomographic imag-
ing was performed (Figure 2).
After each scheduled follow-up period (15, 30 and
60 days), radiotracers were injected for bone assessment.
In vivo images were acquired, and subsequently, the removed
bone was examined for tracer uptake and compared to the
control femur. Nonradioactive grafts and orthotopic homo-
lateral controls were surgically excised simultaneously for
histological analysis. After 60 days, as mentioned above,
CT imaging was also performed for comparison with base-
line findings.
Surgical bone removal revealed major changes in the size,
texture, bone integrity, and surrounding tissues, depending
on the timing of the procedure.
Figure 3 depicts the femur after 15 days of subcutaneous
storage. The femur was swollen and fully covered by an
Figure 2 - Tomographic imaging of an animal immediately after
syngeneic femur implant (upper image) and at 60 days of storage
(lower image). The grafts (arrows) can be identified below the
rib cage. On the 60-day image, the bone resorption is highly
advanced (nearly 50% of the mass). This phenomenon did not
always occur, with other animals exhibiting far less bone loss.
Figure 3 - Syngeneic femur 15 days after implantation in the
abdominal pocket.In the surgical picture, the subcutaneous
tissue where the bone was positioned is swollen and hyperemic,
and dilated blood vessels can be identified nearby. The bone is
also mildly swollen and is fully encased by adherent inflamma-
tory tissue (pseudocapsule). This foreign body-like reaction
included multiple blood capillaries.
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inflammatory pseudocapsule. Both the diaphysis and epi-
physes were widened. Handling of the graft confirmed that it
had become more flexible because of fluid infiltration.
Neither macroscopic bone nor bone marrow necrosis was
prominent.
After 30 and 60 days, the inflammatory tissue reaction
around the bone continued to occur, although less hyperemia
was observed. Bone edema disappeared and was replaced
by progressive brittleness and resorption. By 60 days, bone
resorption and fragmentation were conspicuous, and in
certain animals, as little as 50% of the original femur could be
recovered from the subcutaneous pouch. Bone marrow
changes suggestive of necrosis were also noted at 30 days
and were more remarkable after 60 days (Figures 2 and 4).
Bone weight data are presented in Figure 5. After 15 days,
the grafts were heavier than the controls (p=0.038); how-
ever, these profiles were reversed after 30 and 60 days of
implantation (p=0.035 and p=0.047, respectively).
The uptake of 99mTc-HYNIC-E-c(RGDfK)2 by the control
femurs displayed some fluctuations depending on the time
point, although no significant difference was noted. Among
the grafts, the uptake was highest after 15 days (p=0.016)
and subsequently diminished at 30 and 60 days (p=0.040 and
p=0.043, respectively). Consequently, graft uptake exceeded
that of controls under all circumstances (Figure 6).
No significant differences in 99mTc-MDP were detected
over time among the syngeneic implants or control femurs,
although a tendency toward graft reduction at 30 and
60 days was evident. As expected, the control uptake was
substantially higher than in the ischemic grafts. It should
be emphasized that the avascular graft values were not
negligible, indicating sustained viability and metabolic
activity, as documented with 99mTc-HYNIC-E-c(RGDfK)2
(Figure 7).
Static images obtained with a gamma camera (Figure 8)
revealed the uptake of radiotracers in the entire body and in
the femur grafts after 15 days.
Control femurs exhibited healthy trabeculae and bone
marrow histology at all times, as expected (Figure 9). On
ischemic slides after 15 days, mild marrow and bone edema
could be identified, along with some degree of bone marrow
necrosis (Figure 10).
After 30 days, edema was no longer conspicuous. Some
areas exhibited bone resorption. The bone marrow did
not change substantially compared with that at 15 days
Figure 4 - Pictures of control (upper image) and grafted femur (lower image) at different times. A: 15 days, B: 30 days, C: 60 days. It is
perceived that, after 15 days, the implant is swollen and enlarged. By 30 days, the edema had disappeared and was replaced by bone
dryness and brittleness. However, the structural integrity was mostly maintained. At the last follow-up (60 days), severe bone resorption
and fragmentation in some cases permitted the recovery of as little as 50% of the syngeneic bone only. However, in most animals, bone
destruction was not as advanced as in this picture.
Figure 5 - Femur weight after subcutaneous storage.
Figure 6 - Uptake of 99mTc-HYNIC-E-c(RGDfK)2 in the femur.
Figure 7 - Uptake of 99mTc-MDP in the femur.
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(Figure 11). By 60 days, areas exhibiting extensive destruction
of the bone and bone marrow could be identified. Never-
theless, as at other time points, the femur showed a generally
heterogeneous pattern. Depending on the anatomical location,
areas that were in fairly good histological shape were
identified, whereas other areas revealed severe damage
(Figure 12).
’ DISCUSSION
Osteonecrosis is a condition that results from the tempo-
rary or permanent loss of blood supply to the bone.
Simultaneous direct damage to osteocytes, osteoclasts,
bone marrow and other cells cannot be excluded in many
circumstances, particularly during radiotherapy, alcohol
use, drug use, or endotoxemia, potentially aggravating the
consequences of ischemia. Indeed, some studies have
reported that this difficult-to-define process is more related
to apoptosis than to necrosis (14).
Osteonecrosis has also been designated as avascular,
aseptic, ischemic, subchondral, and subarticular necrosis.
The last two designations refer to its tendency to attack the
epiphyseal regions of long bones Although it might be
completely asymptomatic, when osteonecrosis occurs in
implanted bone, loss of function with permanent disability
or malfunction of the graft is inevitable after major insult
unless the bone can regenerate and rebuild itself sponta-
neously or recover via an intervention (1,2,14).
Figure 8 - Gamma camera imaging of the femur graft after 15 days
of abdominal storage. Left side (99mTc-HYNIC-E-[c(RGDfK)2
region of interest (ROI= 0.5%) and right side 99mTc-MDP uptake
(ROI= 0.10%). The arrows indicate the implanted bone.
Figure 9 - Control femur histology (H&E, 100 X): Bone trabec-
ulae (vertical arrow) and bone marrow (horizontal arrow) were
normal at all times, as expected.
Figure 10 - Implanted femur histology, 15 days (H&E, 100 X): The
horizontal arrow indicates the foci of bone marrow necrosis, and
the vertical arrow indicates an area of edema. Moderately
altered bone trabeculae (not highlighted) could be identified.
Figure 11 - Implanted femur histology, 30 days (H&E, 100 X):
Trabeculae are less sharp and more confluent, consistent with
progressive bone deterioration (arrow). Edema is not prominent.
Bone marrow histology varies from necrotic at some points to
nearly intact at others.
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The first report of drug-related osteonecrosis appeared in
1845 (15). At this time, matches were entering the world
market, and all were made with yellow phosphorus.
Prolonged exposure to this chemical, especially by workers
who manufactured matches, could trigger extensive and
disfiguring necrosis of the mandible. Decades later, yellow
phosphorus was banned, and other molecules were selected
for commercial use.
Calve Legg Perthes disease was first recognized in 1910
(16), and with the progress in orthopedics after World War II,
many investigations into osteonecrosis ensued (1,2,14).
Clinical diagnostic tools for bone loss do not distinguish
among bone matrix turnover changes, cell apoptosis, and
tissue necrosis. Resources include biochemical bone turn-
over markers, such as serum C-telopeptide (CTX), urine
N-telopeptide (NTX), serum bone-specific alkaline phospha-
tase (BALP), serum osteocalcin, and serum procollagen type
1 N-terminal propeptide (PINP). The first two reflect bone
resorption, whereas the latter three are relevant to bone
formation (17,18).
Similarly, photon and X-ray absorptiometry for bone
densitometry depicts the end results of all remodeling
phenomena occurring within the skeleton mass, independent
of their nature (19).
Conventional CT and MRI can accurately identify anato-
mical changes, such as localized erosion and bone loss, and
they can provide clues about necrotic and healthy zones.
Nevertheless, only cumbersome and specialized techniques,
such as micro-CT, micro-MRI, and functional MRI, permit
making inferences about cell metabolism, disease progres-
sion, tissue healing, and other functional processes. Limited
information is available, and no investigation has yet
addressed osteonecrosis or angiogenesis (20,21,22).
Tissue morphofunctional analysis, namely, the histology
and histopathology of bone tissue, is a disease-specific, pre-
cise and reliable technique. It clearly identifies the involve-
ment of bone matrix and various cell lineages in ongoing
changes. This tool was employed here for confirmation
purposes. However, its clinical applications are restricted
because this analysis is a highly invasive, costly, and time-
consuming procedure.
In the current protocol, the diagnosis of osteonecrosis and
angiogenesis was conducted by means of radiotracers and
bone imaging. The terms ‘‘osteonecrosis’’ and ‘‘angiogenesis’’
are employed rather nonspecifically as synonyms of bone
resorption and the restoration of tissue viability, respectively,
because receptor measurements and the quantification of
genetic and molecular markers are not included in the
protocol. The study results were collected using a classic
technique. Technetium-99m methylene diphosphonate
(99mTc-MDP) bone scintigraphy has long been used for the
evaluation of normal bone and bone lesions by chemisorp-
tion, followed by hydroxyapatite exchange with the inor-
ganic matrix of the bone (23,24).
Angiogenesis, which is the process of neovasculature
formation from pre-existing blood vessels, is widely con-
sidered to be essential to ensure the nutrient and oxygen
supply to ischemic tissues (25). No previous reports addres-
sing the direct or indirect assessment of angiogenesis in
avascular bone were found in the literature; thus, to the best
of our knowledge, this work is the first attempt at such an
evaluation.
Angiogenesis involves many mediators, including integ-
rins. The extracellular domains of many integrins recognize
the RGD (Arg-Gly-Asp) tripeptide found in several extra-
cellular macromolecules, such as fibronectin, vitronectin,
fibrinogen and osteopontin (11). This fact was the rationale
underlying the selection of 99mTc-HYNIC-E-c(RGDfK)2 as an
additional radiotracer in this study.
It should be noted that avb3 integrin is expressed in
osteoclasts, which are bone-resorbing cells, and it binds
to some RGD-containing proteins, including osteopontin,
which is abundant in bone. The use of RGD radiotracers has
been experimentally reported in the form of PET-CT for the
identification of osteoclasts (26).
However, RGD is considered a promising agent for
only osteoclast-related diseases, such as Paget’s disease or
rheumatoid arthritis. Osteoclast activity has been reported in
subchondral bone, such as human osteonecrotic femoral
heads, with increased osteoblast expression found in neigh-
boring areas (27). Avascular bone necrosis is not listed
among osteoclast-related diseases, but overlap between angio-
genesis and osteoclast affinity might interfere with the
interpretation of the findings.
For this reason, among others, histological confirmation
was sought to shed light on the potentially conflicting affi-
nities of 99mTc-HYNIC-E-c(RGDfK)2 in this setting.
Experience with abdominal subcutaneous autologous
flaps of calvarial bone stored for periods of two months or
more in the context of severe intracranial hypertension may
be pertinent to the current model, although cancellous bone
is prominent in the skull and not in cortical tissue (3,4,28).
Singla et al. (2014) (12) observed angiogenesis in 14% of
patients. No relationship was noted between angiogenesis
and the duration of bone flap preservation. Six percent of
the bone flaps showed new bone formation. All of the bone
flaps with new bone formation had underlying osteo-
blastic activity. The bone implants were maintained in the
subcutaneous pouch for a highly variable period, usually
between 3 and 12 months.
New bone generation was occasionally detected on
histological slides in this experience; however, bone and
Figure 12 - Implanted femur histology, 60 days (H&E, 100 X):
Bone (upper arrow) and bone marrow (lower double arrows)
degradation is more advanced. However, in keeping with the
findings at 15 and 30 days, the pattern is not homogeneous,
with seriously damaged areas, along with a better preserved
femur.
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bone marrow damage constituted the most noticeable fea-
tures. Nevertheless, one should emphasize the heterogeneity
of the results, which was not perceived in the figures in the
article because representative images were selected. At all of
the follow-ups, but especially after 30 and 60 days, quite
healthy areas were prominent, in contrast with heavily com-
promised skeleton tissue. This finding could be another
limitation of the histological monitoring of bone necrosis
because the interpretation of biopsy material would become
dependent on regional fluctuations in tissue damage.
The same morphological heterogeneity prevented point-
by-point correlations between histology and radiotracer
profiles, which might elucidate nuclear marker affinities in
the ongoing necrosis phenomenon regarding angiogenesis,
new bone synthesis, and osteoclastic resorption. Never-
theless, the tendency toward progressive deterioration in
femur histology from 15 to 60 days was fully compatible
with similar results with 99mTc-MDP, which is a nonspecific
bone health marker. At the same time, the maintenance of
acceptable bone viability despite full ischemia, notably by
15 and 30 days but decaying afterwards, could be easily
explained by active angiogenesis during the early periods, as
suggested by the 99mTc-HYNIC-E-c(RGDfK)2 uptake curve.
It should be noted that ex vivo isotopic samples were
selected here, which is something that is impractical in
patient studies; however, it was only used for greater
accuracy of the experiment. The available clinical scanners
provide sufficient resolution for both purposes envisaged in
the design, namely, the uptake measurements and imaging
studies (9,11,24,29).
There are reasons to believe that periosteal, endosteal, and
medullary cells within 0.2 mm of the bone surface survive
after excision and bone implantation, while most others
succumb (28,30). Moreover, subcutaneous tissue is anatomi-
cally a poorly vascularized bed. Until pouch vasodilatation
and graft angiogenesis occur, which can take days or weeks,
cell death could be inevitable, potentially hampering the
future viability of the graft.
Given that only modified imaging methods, and not
conventional methods (20,21,22), have been deemed suitable
for bone metabolism and viability exploration, there could be
an advantage within this context of considering isotopic
techniques. These procedures were intrinsically functional
and global, depicting all of the anatomical segments targeted
by systemically injected biomarkers. Infarcted areas were
naturally excluded because radionuclide uptake becomes
negligible (29).
The protocol was successful, and a simple, stable and
convenient model was created. At the same time, the two
radiotracers proved easy to employ, and the results were
encouraging. Even in fully ischemic tissue, devoid of any
anatomically recognized blood flow, both were clearly taken
up and could be identified by imaging.
These are comparatively inexpensive and available agents,
at least in institutions with access to nuclear medicine
facilities. Technetium has a chemical half-life of 6 hours and a
biological half-life of 24 hours. Radiotracer studies can be
safely repeated as often as every week, if clinically indi-
cated. Radiotracers deserve investigation in bone grafts and
ischemic bone disease, among other settings, not only in
cases of the abdominal preservation of cranial vault grafts
with the purpose of expanding the current findings but also
in unearthing target-specific biomolecular processes con-
nected to necrotic initiation, progression and resolution.
’ CONCLUSIONS
1) A new experimental model of bone osteonecrosis in
mobile animals was created, which was convenient and
practical, even for relatively long follow-up periods.
2) The diagnosis of graft conditions by systemic radiotracers
was demonstrated for the first time in a totally devascu-
larized major bone structure, thus paving the way for
future studies in additional settings.
3) The histological heterogeneity of bone and bone-marrow
necrosis suggested that global noninvasive functional bone
assessment provided by the isotopes could exceed the
advantages of bone biopsy and other more complex
alternatives.
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